The Company intends to use the net proceeds from this offering to fund Immuron’s
Research and Development, preclinical and clinical programs, support marketing initiatives
surrounding the Company’s flagship product Travelan and provide ongoing working capital for the
Company.
apparently
Ann: Annual Report to shareholders, page-28
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $23.93M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $3.465K | 33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 142457 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 88526 | 3 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| IMC (ASX) Chart |